BCL2L11 Deletion Polymorphism

CI-VAR-00000653Explore in graph →CIViC 526

Curated evidence

Evidence by cancer (3 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–3 of 3 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Chronic Myeloid Leukemia, BCR-ABL1 Positive2
BCL2L11 Deletion Polymorphism	Imatinib	Predictive	B	Supports Resistance	4	accepted	EID1280 DNA sequencing was performed in five Ph+ CML samples with sensitivity or resistance to imatinib. A structural variation in BIM2 (BCL2L11) with an identical 2,903-bp genomic deletion was identified in … (full text at CIViC) PMID 22426421 · Ng et al., 2012 · Open in CIViC	civic
BCL2L11 Deletion Polymorphism	Imatinib	Predictive	B	Supports Sensitivity Response	4	submitted	EID9701 In a clinical study including 200 patients, deletion polymorphism is not significantly associated with resistance to imatinib (p = 0.116). PMID 25295932 · Chen et al., 2014 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.